Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)
Abstract
To determine the efficacy and toxicity of nivolumab monotherapy in treatment-naïve patients with non-clear cell renal cell carcinoma (nccRCC) and the efficacy of nivolumab/ipilimumab salvage therapy in patients with tumors unresponsive to initial nivolumab monotherapy.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 01, 2023
- Source ID
- 10.1136/jitc-2022-004780
Entities
People
- Alessia Cimadamore
- Catherine J Wu
- David A Braun
- David E. Einstein
- David F McDermott
- David J Peace
- Elizabeth R. Plimack
- Hans Hammers
- Jeffrey A. Sosman
- Mark Stein
- Mehmet Asım Bilen
- Michael B Atkins
- Michael Hurwitz
- Moshe C Ornstein
- Naomi B. Haas
- Opeyemi A. Jegede
- Paul J. Catalano
- Robert Alter
- Sabina Signoretti
- Thomas Denize
Organizations
- Bristol-Myers Squibb
- National Cancer Institute
- United States Department of Defense